Skip to content

Study · Animal study (in vivo) · mouse · 2018

9 results

Comparative Study of Liraglutide and Insulin Glargine on Glycemic Control and Pancreatic β-Cell Function in db/db Mice.

Li Y, Zheng J, Shen Y, Li W, Liu M, Wang J, Zhu S, Wu M

Medical science monitor : international medical journal of experimental and clinical research19 May 2018Cited by 9 (Europe PMC)

PMID29777582 (opens in a new tab)PMCIDPMC5987616 (opens in a new tab)DOI10.12659/msm.907227 (opens in a new tab)PepBankPUB-29777582
Read at sourcePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, liraglutide improved glycemic control compared with vehicle.

    In plain wordsIn db/db mice, liraglutide improved blood sugar control compared with vehicle.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedGlycemic control
    Study

    mousen = 32

    db/db mice
    Comparator
    Vehicle
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    75-300 μg/kg · subcutaneous · from 8 to 14 weeks of ageAs given in this study (mouse).

    Source sentences

    Summary
    RESULTS Both insulin glargine and liraglutide improved glycemic control of db/db mice when compared with vehicle.
    1 context sentence
    Summary · context
    Eight-week-old male db/db mice (n=40)
  2. 02AnimalAnimal study (in vivo)Safety outcome

    In db/db mice, liraglutide treatment was without hypoglycemic effects.

    In plain wordsIn db/db mice, liraglutide did not cause low blood sugar.

    Peptide
    Liraglutide
    Outcome
    No significant changeHypoglycemic effects
    Study

    mousen = 24

    db/db mice
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    75-300 μg/kg · subcutaneous · from 8 to 14 weeks of ageAs given in this study (mouse).

    Source sentences

    Summary
    Liraglutide treatment was without hypoglycemic effects.
    1 context sentence
    Summary · context
    Eight-week-old male db/db mice (n=40)
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In db/db mice, the IPGTT ROC area under the curve was significantly higher with high-dose liraglutide than with insulin glargine.

    In plain wordsIn db/db mice, high-dose liraglutide gave a higher glucose tolerance test curve measure than insulin glargine.

    Peptide
    Liraglutide
    Outcome
    IncreaseGlucose tolerance (IPGTT ROC AUC)
    Study

    mousen = 16

    db/db mice
    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    300 μg/kg · subcutaneous · from 8 to 14 weeks of ageAs given in this study (mouse).

    Source sentences

    Summary
    The following were significantly increased in the HLG compared with the GG: the receiver operating characteristic (ROC) area under the curve (AUC) for the IPGTT; C-peptide levels; the pancreas to body weight coefficient; expression levels of the INS1 gene and pancreatic transcription factors Pdx1, Pax4 and Pax6.
    1 context sentence
    Summary · context
    Eight-week-old male db/db mice (n=40)
  4. 04AnimalAnimal study (in vivo)Mechanism

    In db/db mice, C-peptide levels were significantly higher with high-dose liraglutide than with insulin glargine.

    In plain wordsIn db/db mice, high-dose liraglutide gave higher C-peptide levels, a sign of insulin production, than insulin glargine.

    Peptide
    Liraglutide
    Outcome
    IncreaseC-peptide level
    Study

    mousen = 16

    db/db mice
    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    300 μg/kg · subcutaneous · from 8 to 14 weeks of ageAs given in this study (mouse).

    Source sentences

    Summary
    The following were significantly increased in the HLG compared with the GG: the receiver operating characteristic (ROC) area under the curve (AUC) for the IPGTT; C-peptide levels; the pancreas to body weight coefficient; expression levels of the INS1 gene and pancreatic transcription factors Pdx1, Pax4 and Pax6.
    1 context sentence
    Summary · context
    Eight-week-old male db/db mice (n=40)
  5. 05AnimalAnimal study (in vivo)Mechanism

    In db/db mice, the pancreas to body weight coefficient was significantly higher with high-dose liraglutide than with insulin glargine.

    In plain wordsIn db/db mice, high-dose liraglutide gave a higher pancreas to body weight ratio than insulin glargine.

    Peptide
    Liraglutide
    Outcome
    IncreasePancreas to body weight coefficient
    Study

    mousen = 16

    db/db mice
    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    300 μg/kg · subcutaneous · from 8 to 14 weeks of ageAs given in this study (mouse).

    Source sentences

    Summary
    The following were significantly increased in the HLG compared with the GG: the receiver operating characteristic (ROC) area under the curve (AUC) for the IPGTT; C-peptide levels; the pancreas to body weight coefficient; expression levels of the INS1 gene and pancreatic transcription factors Pdx1, Pax4 and Pax6.
    1 context sentence
    Summary · context
    Eight-week-old male db/db mice (n=40)
  6. 06AnimalAnimal study (in vivo)Mechanism

    In db/db mice, INS1 gene expression was significantly higher with high-dose liraglutide than with insulin glargine.

    In plain wordsIn db/db mice, high-dose liraglutide gave higher expression of the insulin gene INS1 than insulin glargine.

    Peptide
    Liraglutide
    Outcome
    IncreaseINS1 gene expression
    Study

    mousen = 16

    db/db mice
    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    300 μg/kg · subcutaneous · from 8 to 14 weeks of ageAs given in this study (mouse).

    Source sentences

    Summary
    The following were significantly increased in the HLG compared with the GG: the receiver operating characteristic (ROC) area under the curve (AUC) for the IPGTT; C-peptide levels; the pancreas to body weight coefficient; expression levels of the INS1 gene and pancreatic transcription factors Pdx1, Pax4 and Pax6.
    1 context sentence
    Summary · context
    Eight-week-old male db/db mice (n=40)
  7. 07AnimalAnimal study (in vivo)Mechanism

    In db/db mice, Pdx1 expression was significantly higher with high-dose liraglutide than with insulin glargine.

    In plain wordsIn db/db mice, high-dose liraglutide gave higher expression of the pancreatic factor Pdx1 than insulin glargine.

    Peptide
    Liraglutide
    Outcome
    IncreasePdx1 mRNA expression
    Study

    mousen = 16

    db/db mice
    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    300 μg/kg · subcutaneous · from 8 to 14 weeks of ageAs given in this study (mouse).

    Source sentences

    Summary
    The following were significantly increased in the HLG compared with the GG: the receiver operating characteristic (ROC) area under the curve (AUC) for the IPGTT; C-peptide levels; the pancreas to body weight coefficient; expression levels of the INS1 gene and pancreatic transcription factors Pdx1, Pax4 and Pax6.
    1 context sentence
    Summary · context
    Eight-week-old male db/db mice (n=40)
  8. 08AnimalAnimal study (in vivo)Mechanism

    In db/db mice, Pax4 expression was significantly higher with high-dose liraglutide than with insulin glargine.

    In plain wordsIn db/db mice, high-dose liraglutide gave higher expression of the pancreatic factor Pax4 than insulin glargine.

    Peptide
    Liraglutide
    Outcome
    IncreasePax4 mRNA expression
    Study

    mousen = 16

    db/db mice
    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    300 μg/kg · subcutaneous · from 8 to 14 weeks of ageAs given in this study (mouse).

    Source sentences

    Summary
    The following were significantly increased in the HLG compared with the GG: the receiver operating characteristic (ROC) area under the curve (AUC) for the IPGTT; C-peptide levels; the pancreas to body weight coefficient; expression levels of the INS1 gene and pancreatic transcription factors Pdx1, Pax4 and Pax6.
    1 context sentence
    Summary · context
    Eight-week-old male db/db mice (n=40)
  9. 09AnimalAnimal study (in vivo)Mechanism

    In db/db mice, Pax6 expression was significantly higher with high-dose liraglutide than with insulin glargine.

    In plain wordsIn db/db mice, high-dose liraglutide gave higher expression of the pancreatic factor Pax6 than insulin glargine.

    Peptide
    Liraglutide
    Outcome
    IncreasePax6 mRNA expression
    Study

    mousen = 16

    db/db mice
    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    300 μg/kg · subcutaneous · from 8 to 14 weeks of ageAs given in this study (mouse).

    Source sentences

    Summary
    The following were significantly increased in the HLG compared with the GG: the receiver operating characteristic (ROC) area under the curve (AUC) for the IPGTT; C-peptide levels; the pancreas to body weight coefficient; expression levels of the INS1 gene and pancreatic transcription factors Pdx1, Pax4 and Pax6.
    1 context sentence
    Summary · context
    Eight-week-old male db/db mice (n=40)

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.